SwiftDx’s portfolio of patented technologies enable highly sensitive lateral flow diagnostics for diseases which are undetectable with current lateral flow test technology. To accelerate SwiftDx's work in prostate cancer they are interested in making connections with companies developing feasible biomarkers.
If you are a company/academic developing suitable biomarkers, please complete the form below to register your interest.
